LSC
ALDR

Lesa Sroufe & Co’s Alder Biopharmaceuticals ALDR Stock Holding History

Lesa Sroufe & Co’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-129,267
Closed -$1.48M – 41
2017
Q2 		$1.48M Buy
+129,267
New +$2.39M 1.37% 27

Other funds holding ALDR

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Lesa Sroufe & Co's ALDR Position: Q3 2017 in Review

Lesa Sroufe & Co sold out of Alder Biopharmaceuticals (ALDR) in Q3 2017, closing a stake of 129,267 shares — an estimated $1.48M sold.

Lesa Sroufe & Co first reported a position in ALDR in Q2 2017 and held it in 1 quarter. The position peaked at $1.48M in Q2 2017. 132 funds tracked by Wall St. Rank hold ALDR as of Q3 2017.

  • Lesa Sroufe & Co reported no remaining Alder Biopharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Lesa Sroufe & Co sold 129,267 Alder Biopharmaceuticals shares in Q3 2017, an estimated $1.48M.
  • Lesa Sroufe & Co first reported a position in Alder Biopharmaceuticals in Q2 2017 and held it in 1 quarter.
  • Lesa Sroufe & Co's Alder Biopharmaceuticals position peaked at $1.48M in Q2 2017.
  • 132 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q3 2017.

Based on Lesa Sroufe & Co's 13F filing for Q3 2017, filed 8 Nov 2017.